The Total Artificial Heart in End-Stage Congenital Heart Disease

Area of Science:

• Cardiology
• Medical Devices
• Congenital Heart Disease

Background:

• Ventricular assist devices (VADs) have improved outcomes for end-stage heart failure.
• Growing population of end-stage congenital heart disease (CHD) patients require advanced treatment options.
• Anatomical and physiological complexities in CHD limit traditional VAD use.

Purpose of the Study:

• To review the potential application of the total artificial heart (TAH) in patients with complex congenital heart disease (CHD).
• To explore how TAHs can overcome limitations of VADs in CHD patients.

Main Methods:

• Literature review of existing studies and case reports on TAH implantation in CHD patients.
• Analysis of anatomical and physiological challenges in CHD that TAHs can address.
• Discussion of TAH design flexibility in accommodating varied CHD anatomies.

Main Results:

• TAHs, with their adaptable pump orientation, can manage the diverse anatomical variations seen in CHD.
• TAHs present a viable alternative where conventional VADs are contraindicated due to complex CHD anatomy.
• Limited but growing experience suggests TAHs can be effective in select CHD populations.

Conclusions:

• The total artificial heart (TAH) shows significant potential for managing end-stage heart failure in complex congenital heart disease (CHD) patients.
• TAHs offer a more adaptable solution compared to VADs for the unique anatomical challenges in CHD.
• Further research and clinical experience are needed to fully establish TAHs as a standard treatment for this population.